Table 4.
Demographic data for patients who switched biologic agents from TNF inhibitors to subsequent agents
| All patients n = 105 |
TNF inhibitors n = 31 |
IL-12/23 inhibitor n = 19 |
IL-17 inhibitors n = 42 |
IL-23 inhibitors n = 13 |
|
|---|---|---|---|---|---|
| Drug, n |
Adalimumab, 20 Certolizumab pegol, 1 Infliximab, 10 |
Ustekinumab, 19 |
Secukinumab, 19 Brodalumab, 9 Ixekizumab, 14 |
Guselkumab, 11 Risankizumab, 1 Tildrakizumab, 1 |
|
| Age, mean ± SD, years | 51.7 ± 14.2 | 50.0 ± 12.7 | 49.5 ± 16.1 | 53.1 ± 13.5 | 54.2 ± 15.9 |
| Sex (male), n (%) | 68 (65) | 22 (70) | 12 (63) | 27 (64) | 7 (54) |
| Median treatment duration, days (interquartile range, days) | 766 (273–1561) | 607 (168.5–1758.5) | 1916 (1372–2569.5) | 677 (272.5–979) | 759 (122–1067) |
| BMI, mean ± SD | 25.8 ± 4.4 (n = 97) | 26.8 ± 3.8 (n = 31) | 25.4 ± 4.4 (n = 18) | 25.4 ± 4.4 (n = 37) | 26.6 ± 5.6 (n = 11) |
| Previous drug, n |
Adalimumab, 58 Certolizumab pegol, 3 Infliximab, 44 |
Adalimumab, 11 Certolizumab pegol, 1 Infliximab, 19 |
Adalimumab, 10 Certolizumab pegol, 0 Infliximab, 9 |
Adalimumab, 27 Certolizumab pegol, 1 Infliximab, 14 |
Adalimumab, 10 Certolizumab pegol, 1 Infliximab, 2 |
| PsA, n (%) | 58 (55) | 23 (74) | 8 (42) | 23 (55) | 4 (31) |
| GPP, n (%) | 9 (9) | 3 (10) | 2 (11) | 3 (7) | 1 (2) |
| Drug discontinuation, n (%) | 60 (57) | 25 (80) | 14 (73) | 16 (38) | 5 (38) |
| Reasons for drug discontinuation | |||||
| Ineffectiveness, n | n = 39 | n = 15 | n = 10 | n = 10 | n = 4 |
| Adverse events, n | n = 10 | n = 6 | n = 1 | n = 2 | n = 1 |
| Other, n | n = 11 | n = 4 | n = 3 | n = 4 | n = 0 |
BMI body mass index, PsA psoriatic arthritis, GPP generalized pustular psoriasis, TNF tumor necrosis factor